Sheppard Mullin Represents Vigene Biosciences in $350M Sale to Charles River Laboratories
Sheppard Mullin advised Vigene Biosciences, a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions, in its agreement to be acquired by Charles River Laboratories International, Inc. (NYSE: CRL) for $350 million.
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. The transaction is expected to close in the beginning of the third quarter of 2021, subject to regulatory requirements and customary closing conditions.
The Sheppard Mullin team was led by partner Shon Glusky and included partners Leo Caseria and Dmitriy Chelnitsky, special counsel Malika Levarlet and associate Brian Egan.
Click here to read the press release.